---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-007720"
form_type: "8-K"
ticker: "MLAB"
cik: "0000724004"
company_name: "MESA LABORATORIES INC /CO/"
filed_at: "2022-03-30T23:59:59+00:00"
generated_at: "2026-06-26T14:06:47.043956+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Mesa files Agena financials post-acquisition; revises segment reporting structure

## Summary
- Agena's revenue for nine months ended Sep 30, 2021: $58.4M, up 45% YoY; net income of $12.8M vs loss of $0.38M.
- Mesa recast FY2021 segment data into four segments: Sterilization/Disinfection, Clinical Genomics (Agena), Biopharma Development, Calibration Solutions.
- Pro forma combined statement for nine months ended Dec 31, 2021 filed; acquisition closed Oct 20, 2021.
- Agena's cash and equivalents fell to $3.7M from $16.1M at Dec 31, 2020; debt repaid $22.5M during period.

## SEC filing metadata
- accession: 0001437749-22-007720
- form_type: 8-K
- ticker: MLAB
- cik: 0000724004
- company_name: MESA LABORATORIES INC /CO/
- filed_at: 2022-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/724004/000143774922007720/0001437749-22-007720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/724004/000143774922007720/mlab20220309_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-007720
- JSON: https://secwatch.observer/filing/0001437749-22-007720.json
- Plain text: https://secwatch.observer/filing/0001437749-22-007720.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.